Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01382797 · ClinicalTrials.gov registry record · Phase 2

ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)

A Phase 2 study, sponsored by Alkermes.

Completed
Registry status
Phase 2
Development phase
157
Enrollment target

NCT01382797: Completed Phase 2 study, sponsored by Alkermes.

NCT01382797 is a Phase 2 study that has completed, run by Alkermes. The registered enrollment target is 157 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01382797, a Phase 2 study, has completed, sponsored by Alkermes.

COMPLETED
Registry status
Phase 2
Development phase
157 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of ALKS 37 when administered daily for 4 weeks to adults with Opioid-induced Constipation (OIC).

Primary Outcome

Overall response will be defined using an algorithm that takes into consideration number of complete spontaneous bowel movements, improvement from baseline, and durability of response.

Interventions

  • DRUG Placebo
  • DRUG ALKS 37

Trial Details

FieldValue
Enrollment Target 157 participants
Start Date 2011-08
Est. Completion 2012-04
Phase Phase 2
Alkermes

66 total trials

What the finished NCT01382797 record still lists

NCT01382797 is an interventional study that assigns participants to a tested intervention. The registered 157 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (18% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01382797 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01382797 about?

NCT01382797 is a clinical study titled "ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)". The purpose of this study is to evaluate the safety, tolerability and efficacy of ALKS 37 when administered daily for 4 weeks to adults with Opioid-induced Constipation (OIC).

What is the current status of trial NCT01382797?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2011-08. Estimated completion is 2012-04.

What interventions are being tested in trial NCT01382797?

The interventions under investigation include: Placebo (DRUG), ALKS 37 (DRUG).

Who is sponsoring clinical trial NCT01382797?

This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01382797's enrollment target sits among peer trials

157 443rd of 2000 higher than 1,556 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05052541 · 157 participants · Phase 3

    Safety and Efficacy of Oral Cannabis in Chronic Spine Pain

  • NCT05076942 · 157 participants · Phase 2

    Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

  • NCT06396598 · 157 participants · NA

    Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer

  • NCT06655246 · 157 participants · Phase 1

    A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01382797, the US trial registry maintained by the National Library of Medicine. NCT01382797 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.